Salmeterol/fluticasone propionate (50/100 ?g) in combination in a Diskus? inhaler (Seretide?) is effective and safe in children with asthma
- 1 August 2000
- journal article
- clinical trial
- Published by Wiley in Pediatric Pulmonology
- Vol. 30 (2), 97-105
- https://doi.org/10.1002/1099-0496(200008)30:2<97::aid-ppul4>3.0.co;2-p
Abstract
The aim of this study was to compare the efficacy and safety in children of salmeterol (50 μg twice daily) plus fluticasone propionate (100 μg twice daily) when delivered together via a single Diskus™ inhaler (Seretide™; combination therapy) or concurrently using two separate Diskus™ inhalers (concurrent therapy). In a multicenter, randomized, double-blind, double-dummy, parallel-group study, 257 children with reversible airways obstruction who remained symptomatic on inhaled corticosteroids (200–500 μg daily) alone were randomized to combination or concurrent therapy for 12 weeks. Efficacy was assessed by measuring daily peak expiratory flow (PEF), symptom scores, and rescue salbutamol use. In addition, lung function tests were performed at each clinic visit. Safety assessments included monitoring of adverse events and morning serum cortisol concentrations. The primary efficacy parameter (mean morning PEF) increased during treatment in both groups; adjusted mean changes were 33 and 28 L/min for the combination and concurrent therapies, respectively. The 90% confidence interval for the difference in mean morning PEF between treatment groups was within the +15 L/min criterion for clinical equivalence. Similarly, there were improvements in pulmonary function, symptom score, and rescue salbutamol use during treatment in both groups, with no significant differences between the combination and concurrent therapy groups for any of these secondary efficacy parameters. Both treatment regimens were well-tolerated and had comparable adverse event profiles. Mean morning serum cortisol levels increased similarly in both groups during the study. In conclusion, salmeterol and fluticasone propionate therapy given as a new combination product is as safe and effective in children with asthma as the same drugs given concurrently via separate inhalers. Pediatr Pulmonol. 2000; 30:97–105.Keywords
This publication has 24 references indexed in Scilit:
- Growth in asthmatic children treated with fluticasone propionateThe Journal of Pediatrics, 1998
- Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic childrenEuropean Respiratory Journal, 1998
- Compliance with inhaled asthma medication in preschool children.Thorax, 1995
- Bloodspot cortisol in mild asthma: the effect of inhaled corticosteroids.Archives of Disease in Childhood, 1995
- Comparison of DiskusTMInhaler, a New Multidose Powder Inhaler, with DiskhalerTMInhaler for the Delivery of Salmeterol to Asthmatic PatientsJournal of Asthma, 1995
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- Inhaled Fluticasone PropionateDrugs, 1994
- Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma.Archives of Disease in Childhood, 1993
- Increase in hospital admissions for childhood asthma: trends in referral, severity, and readmissions from 1970 to 1985 in a health region of the United Kingdom.Thorax, 1989
- NOCTURNAL ADRENAL SUPPRESSION IN ASTHMATIC CHILDREN TAKING INHALED BECLOMETHASONE DIPROPIONATEThe Lancet, 1986